Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Key Stats

• Today's Range: $6.93 to $7.33
• 50-Day Range: $6.95 to $9.30
• 52-Week Range: $6.10 to $28.67
• Volume: 242,711 shs
• Average Volume: 391,548 shs
• Market Capitalization: $481.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Moderate Buy

Bicycle Therapeutics Stock Analysis - MarketRank™

Bicycle Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 254th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bicycle Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bicycle Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bicycle Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bicycle Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.64% of the float of Bicycle Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicycle Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Bicycle Therapeutics has recently decreased by 28.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicycle Therapeutics does not currently pay a dividend.

Dividend Growth

Bicycle Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.64% of the float of Bicycle Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicycle Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Bicycle Therapeutics has recently decreased by 28.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Bicycle Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Bicycle Therapeutics this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for BCYC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,710.00 in company stock.

Percentage Held by Insiders

22.90% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BCYC Stock Analysis - Frequently Asked Questions

How have BCYC shares performed this year?

Bicycle Therapeutics' stock was trading at $14.00 on January 1st, 2025. Since then, BCYC shares have decreased by 50.4% and is now trading at $6.95.
View the best growth stocks for 2025 here.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) posted its earnings results on Thursday, May, 1st. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The company had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. Bicycle Therapeutics had a negative net margin of 790.07% and a negative trailing twelve-month return on equity of 25.54%.

When did Bicycle Therapeutics IPO?

Bicycle Therapeutics (BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCYC
• CIK: 1761612
• Web: www.bicycletherapeutics.com
• Phone: 441223261503
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $48.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +259.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.03 million
• Net Margins: -790.07%
• Pretax Margin: -811.46%
• Return on Equity: -25.54%
• Return on Assets: -21.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.86
• Quick Ratio: 14.86

Sales & Book Value

• Annual Sales: $35.28 million
• Price / Sales: 13.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.48 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 69,250,000
• Free Float: 63,367,000
• Market Cap: $481.29 million
• Optionable: Optionable
• Beta: 1.46